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Eric B. Schneider, PhD, Thomas Reifsnyder, MD, Julie A. Freischlag, MD, and Bruce A. Perler, MD,
Baltimore, Md
Objective: To evaluate the contemporary outcome of femoral-popliteal bypass compared with angioplasty and stenting in
patients with symptomatic peripheral arterial disease (PAD) in terms of patency and reintervention rates.
Methods:We identiﬁed all patients evaluated at the Johns Hopkins BayviewMedical Center with the presumptive diagnosis
of PAD from September 2005 to September 2010. In this group, we selected all symptomatic patients after failing
medical management who received percutaneous transluminal angioplasty/stenting of the superﬁcial femoral artery or
femoral-popliteal bypass. We compared the overall patency and reintervention rates between the two groups as well as
patency within TransAtlantic Inter-Society Consensus (TASC) II subgroups. Descriptive analyses were performed using
c2 and two-sided t-tests. The Mann-Whitney U test was used to compare distributions of continuous variables and the
Fisher exact test for categorical variables. Cox proportional hazard model was used to examine the treatment effect within
each lesion type, using bypass as the reference group.
Results: Out of 1237 patients evaluated at Johns Hopkins Bayview Medical Center for PAD from September 2005 to
September 2010, we identiﬁed 104 symptomatic patients who received percutaneous transluminal angioplasty/stenting
of the superﬁcial femoral artery or femoral-popliteal bypass after failing medical management. There were 61 male
patients (56%), and the mean age was 68 years in both groups. Both treatment groups had similar risk factors. Overall,
77% of patients with TASC II A and B lesions underwent angioplasty and stenting, whereas 73% of patients with TASC C
and D lesions underwent bypass (P < .01). The primary patency at 24 months was better for the stent group 67% (95%
conﬁdence interval [CI], 0.52-0.78) vs bypass group 49% (95% CI, 0.32-0.64; P[ .05). The rate of reintervention within
the 2-year period was higher in the bypass group compared with the stent group (54% vs 31%; P[ .02). TASC A and B
lesions combined demonstrated a reduced hazard of patency failure compared with TASC C or D lesions combined
(hazard ratio, 2.42; 95% CI, 1.26, 4.65; P < .01).
Conclusions: This is the ﬁrst study that documents higher reintervention rates for femoral-popliteal bypass compared with
angioplasty and stenting. We believe that the main reason for this ﬁnding is the fact that the bypass patients had
signiﬁcantly more advanced disease. This, emphasizes that one must consider the patient population undergoing inter-
vention when comparing revascularization procedures. A prospective randomized trial is needed to determine the overall
better treatment option. (J Vasc Surg 2014;59:129-35.)Surgical bypass using autogenous vein or prosthetic
conduits, with the former being superior in patency, has
been established as the gold standard revascularization
method for the occluded superﬁcial femoral artery (SFA) in
intermittent claudication patients who failed medical
management or in patients presenting with critical limb
ischemia.1-3 The 5-year primary patency rate of femoral-
popliteal above the knee bypass with autogenous saphenous
vein is 70%, while the primary-assisted patency can be
improved to approximately 80%.1 However, this method
of treatment is invasive, with long incisions in the lowerthe Department of Vascular and Endovascular Surgery, Johns
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There is signiﬁcant morbidity (10%-20%) and low but
potential mortality (1%-2%) associated with the surgical
approach.4,5 As vascular surgeons becamemore experienced
with catheter-based procedures in other vascular beds, they
have adapted the minimally invasive percutaneous approach
for lower extremity revascularization, with balloon angio-
plasty (PTA) with or without stenting (S) being the most
widely accepted endovascular option. The outcome of
PTA6 S in the SFAhas been studied previously in retrospec-
tive series, which suggested primary patency rates of 60% at
36-month follow-up.6 There is evidence that shorter lesions
(TransAtlantic Inter-Society Consensus [TASC] II A and B)
dowell with PTA/S,while longer lesions (TASC IIC andD)
have signiﬁcantly lower patency rates.6-8 The latest TASC II
recommendations include an endovascular approach for
shorter lesions and a bypass for longer lesions.5 However,
given patients’ demand for minimally invasive procedures,
the current practice has focused on an endovascular-ﬁrst
approach for most patients, reserving open bypass for
patients who failed that option. Our study seeks to evaluate
if this practice is changing the pattern of patency for both
treatment options.129
JOURNAL OF VASCULAR SURGERY
130 Malas et al January 2014METHODS
Subjects. We reviewed the electronic medical records of
all patients who presented to the Johns Hopkins Bayview
Medical Center with intermittent claudication, rest pain,
tissue loss, or gangrene of the lower extremities between
September 1, 2005 and June 30, 2012. The Institutional
Review Board under the Johns Hopkins Vascular Registry
approved data collection. Patients were identiﬁed using
the International Classiﬁcation of Diseases, Ninth Revision
codes appropriate to diagnosis of peripheral arterial disease
(PAD) with all the possible presenting symptoms (440.20,
440.21, 440.22, 440.23, and 440.24). All symptomatic
patients underwent noninvasive arterial Doppler studies.
Only patients who had an abnormal arterial Doppler study
(deﬁned as ankle brachial index [ABI] < 0.9 or toe brachial
index <0.65 conﬁrming arterial insufﬁciency) were selected
for this study. All patients with noncritical limb ischemia
were advised to follow a structured exercise program with
follow-up in 3-6 months or earlier if they experienced wors-
ening of symptoms. Cilostazol was often prescribed for the
patients to improve walking distance. Aggressive manage-
ment of patients’ risk factors was implemented including
smoking cessation, antiplatelet therapy, and aggressive
hypertension, hypercholesterolemia, and diabetes control.
Only patients who failed conservative medical management
with no improvement orworsening of claudication symptoms
preventing them from performing their daily activities or
patients presenting with critical limb ischemia underwent
diagnostic angiography. Of the entire group, we included
patientswho received femoral-popliteal bypass (bypass group)
or angioplasty and stenting of the femoral and/or above the
knee popliteal artery (stent group).
Data. Patient age, sex, smoking status, andcomorbidities
(diabetes, hypertension, coronary artery disease [CAD],
hyperlipidemia, cerebrovascular disease, and chronic obstruc-
tive pulmonarydisease)were recorded. Patient symptoms and
clinical ﬁndings were identiﬁed. Indications for the procedure
were recorded, andABI for each patient was recorded. Lesion
characteristics indentiﬁed on diagnostic angiography by the
operating surgeon were reported in accordance with the
TASC II classiﬁcation standard.5 A second independent
reviewer on the research team veriﬁed all lesions’ TASC II
classiﬁcation.
Treatment strategy. Most patients with extensive
lesions (TASC II C and D) were offered bypass surgery.
Few patients with extensive lesions but whowere considered
high risk for surgerywere treatedwith PTA/S.Most patients
with less extensive lesions (TASC II A and B) were treated
with PTA/S during the initial angiography. Few patients
who could not be treated with the PTA/S because of difﬁ-
culty crossing the lesions were offered bypass surgery.
PTA/S techniques. All PTA/S were performed either
in the interventional radiology or hybrid endovascular
operating suite, both with ﬁxed imaging capabilities. Arte-
rial access was usually obtained from contralateral groin to
evaluate the inﬂow vessels, followed by an up an over access
of the affected limb and placement of a 40-cm 6F Balkinsheath (Cook Peripheral Inc, Bloomington, Ind). Few
patients with difﬁcult tortuous aortoiliac anatomy under-
went antegrade access on the affected limb. Patients with
normal renal function received Omnipaque contrast
(General Electric Health Care Inc, Princeton NJ) using
power injector. Patients with creatinine 1.5-2.0 received
preoperative hydration with standard bicarbonate infusion,
whereas Visipaque (General Electric Health Care Inc) was
used for contrast. Patients with creatinine greater than 2.0
received angiography with carbon dioxide and minimal
amount of Visipaque (<30 cc) through selective catheter-
ization. Accurate measurement of lesions length and vessel
diameter were obtained utilizing marker catheter or tape
and calibration technique. Distal run off vessels were
documented prior to crossing the lesions. All patients were
systemically anticoagulated with heparin (60-80 IU/kg).
Lesions were crossed with glide wire and angled tapered
glide catheter (Terumo Medical Corporation, Somerset,
NJ). Subintimal technique was used for most complete
occlusive lesions. A re-entry device, the Outback (Cordis,
Bridgewater, NJ) was needed in very few patients. Angio-
graphic conﬁrmation of re-entry into the true lumen was
documented. PTA was performed on all patients utilizing
4-6 mm diameter and appropriate length balloons.
We attempted crossing all lesions including TASC II C
and D lesions. Patients with lesions extending proximal to
2 cm below the origin of the SFA or distal to the level of
the medial epicondyle into the popliteal artery were offered
surgery. All patients received a self-expanding noncovered
nitinol stent from various manufacturers (Absolute; Abbott
Vascular, Santa Clara Calif, Smart; Cordis, Zilver; Cook
Peripheral Inc, Luminex and Life; Bard Inc, Murray Hill
NJ). A single stent was preferred to cover the entire lesion
plus at least 0.5 cm proximal and 0.5 cm distal to the target
lesion. Stent diameter was determined to oversize the orig-
inal vessel diameter by approximately 1 mm. When more
than one stent was used, we overlapped the stent by at least
1 cm. All stents were ballooned to ensure proper opposi-
tion to the vessel wall. The ﬁnal angiogram documented
normal ﬂow in the stented lesions and runoff vessels. Post-
operatively, all patients received loading dose of 300 mg of
clopidogrel (Bristol-Myers Squibb, New York, NY) fol-
lowed by 75 mg daily for at least 4-6 weeks and 81 mg
of aspirin daily indeﬁnitely. Statin-based drugs were used
in patients with hyperlipidemia.
Bypass techniques. Patients received preoperative beta
blockade and statin medications and continued with aspirin
therapy. All patients underwent preoperative venous
mapping in our vascular laboratory. Veins with diameter
equal to or greater than 3.5 mm were considered adequate
conduits for bypass. Techniques for surgical bypass included
using autogenous veins, reversed or in situ. Arm veins were
used in few patients when the greater saphenous veins were
previously used. Spliced autogenous vein graft was used if
a single vein segment was inadequate in length. Synthetic
polytetraﬂuoroethylene (PTFE) grafts were rarely used
only if autogenous veins were unavailable.
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clinic postoperatively. Patients were scheduled and encour-
aged to follow-up at 1, 3, 6, and 12 months during the
ﬁrst postoperative year and yearly thereafter. Noninvasive
testing including duplex ultrasound and ABIs were per-
formed at follow-up visits. Patients were contacted by phone
and mail if lost to follow-up. Social security death index was
used to determine mortality for loss of contact patients.
Patient risk modiﬁcations were emphasized during the
follow-up visits including smoking cessation and nicotine
replacement therapy, antiplatelet and tight hypercholester-
olemia control with target low-density lipoprotein of <75
mg/dL and hyperglycemia control with target A1c of <53
mmol/mol (7.0%). This was carefully communicated with
the primary care giver and/or the primary cardiologist.
Outcome assessment. Patency was determined by
vascular duplex ultrasound study and ABI in conjunction
with pulse examination. Duplex criteria for signiﬁcant
(>50%) stenosis was deﬁned as loss of reverse ﬂow; marked
spectral broadening; blunted waveform distal to stenosis as
well as increased peak systolic velocity >300 cm/s in-stent
or bypass graft, or a ratio of >3.0 of the stenosed segment
highest velocity to the immediate proximal normal segment
velocity or end diastolic velocity <45 cm/s in the bypass
graft.9 An angiogram was performed in patients with
signiﬁcant restenosis. If the stenosis was conﬁrmed to be
greater than 50% on angiography, reintervention was per-
formed. Primary patency was calculated from the time of the
initial revascularization procedure until an intervention was
performed for restenosis or until there was complete occlu-
sion/thrombosis of the bypass or stent. Patients who had an
intervention for restenosis, not occlusion, contributed to
primary-assisted patency. Primary-assisted patency was
calculated from the time of the initial revascularization
procedure through reintervention procedure until there was
complete occlusion on duplex or angiogram.
Methods of reintervention. Vein grafts with stenotic
lesions shorter than 3 cm were treated with angioplasty.
For lesions longer than 3 cm or if restenosis occurred after
two angioplasty procedures, veins grafts were treated with
open patch angioplasty or interposition vein grafts for long
lesions. Treatment of in-stent restenosis and intimal hyper-
plasia was accomplished with angioplasty alone. Restenting
was reserved for fractured stents only.
Statistical analysis. Descriptive statistics were calcu-
lated using two-sided t-tests, c2 (Pearson and Fisher exact)
tests to evaluate differences in patient demographics and
comorbidities between treatment groups. The c2 tests
(Pearson and Fisher exact) were also used to evaluate
differences in TASC II classiﬁcation. Using the Kaplan-
Meier survival estimates, the overall patency (primary and
primary-assisted) was compared between the two treatment
groups, with the bypass group as the reference. Patient data
were censored if patients were lost to follow-up and were
considered a failure at the time there was a terminating event
(patency failure, mortality, and limb loss). Log-rank tests
calculated differences in patency rates (primary and primary-
assisted) between the two treatment groups. Kaplan-Meierestimates were also used to compare primary patency and
primary-assisted patency within TASC II subgroups. Using
the Cox-proportional hazard regression model with robust
variance,10 we performed univariate analysis to estimate the
crude hazard ratio (HR) of failure associated with procedure
type with the bypass group as the reference. A univariate
analysis of HR of failure was also performed for other patient
risk factors. Subsequently, adjusted Cox proportional HRs
were calculated comparing stent placement to bypass
controlling for TASC II lesion types, age, sex, smoking
history, hypertension, CAD, cerebrovascular accident, and
chronic obstructive pulmonary disease. To estimate differ-
ences between the two treatment groups, the Fischer exact
test was used to estimate P values for categorical variables,
while the two-sided t-test was used for continuous variables.
Partial likelihood ratio test were used to ﬁt the best
model for our multivariable Cox regression analysis. All
statistical analysis was done using Stata MP v. 11.0 (Stata-
Corp, College Station, Tex). Statistical signiﬁcance was
deﬁned as P < .05.
RESULTS
There were 1237 patients who presented with presump-
tive diagnosis of PAD in outpatient and inpatient settings at
JohnsHopkins BayviewMedicalCenter between September
1, 2005 and June 30, 2012. Only 104 patients (8%) ﬁt the
inclusion criteria of the study, among which 61 received
PTA/S, whereas 43 received femoral-popliteal bypass
(37 with veins and six with PTFE grafts). All synthetic grafts
were used for above-the-knee bypass. There were 13 below-
the-knee bypasses all with veins.
The follow-up periodhad amaximumof 81monthswith
a median follow-up of 24 months and a mean follow-up of
26 months. We have excluded one patient who had no
follow-up at all after the initial procedure.
Approximately, one-half of the patients (n ¼ 53; 51%)
presented with critical limb ischemia, of which 23 patients
(22%) had rest pain and 30 patients (29%) had tissue loss
and gangrene. Intermittent claudication was the presenting
symptom in 51 patients (49%). The distribution of intermit-
tent claudication vs critical limb ischemia was similar in both
treatment groups. The baseline patient characteristics are
illustrated in Table I. Patients’ mean age was similar in
both treatment groups: 65.8 (95% conﬁdence interval
[CI], 62.8-68.7) in the bypass group and 65.6 (95% CI,
62.7-68.6; P¼ .96) in the stent group. There were 61males
(58.7%) and 43 females (41.4%). The stent group had similar
sex distribution (54% males vs 46% females), whereas the
bypass group had more males (65% males vs 35% female).
However, the distribution of sex between the two groups
was not signiﬁcantly different (P ¼ .26).
The prevalence of cardiovascular risk factors (hyperten-
sion, CAD, cerebrovascular accident, smoking, and dyslipide-
mia) was similar across groups, except for diabetes, which was
marginally higher in the stent group (64% vs 46%; P ¼ .07).
The majority of patients had TASC B lesions (n ¼ 43),
followed by TASC D (n ¼ 29), TASC A (n ¼ 23), and
TASC C (n ¼ 9). Overall, 77% of patients with TASC A
Fig 1. Primary patency in the stent group compared with the
bypass group.
Table I. Patient demographics and risk factors
Bypass group
(n ¼ 43)
Stent graft group
(n ¼ 61) P value
Mean age, years 65.8 (62.8-68.7) 65.6 (62.7-68.6) .96a
Sex .26b
Male (n ¼ 61;
58.7%)
28 (65%) 33 (54%)
Female (n ¼ 43;
41.4%)
15 (35%) 28 (46%)
Smoking history 28 (65%) 43 (70%) .69b
Diabetes 20 (46%) 39 (64%) .07b
CAD 27 (63%) 34 (56%) .47b
Hypertension 33 (77%) 49 (82%) .65b
Hyperlipidemia 32 (74%) 50 (82%) .35b
CVA 4 (9.3%) 3 (4.9%) .38b
COPD 8 (19%) 17 (28%) .27b
TASC II category <.01b
A 2 (8.7%) 21 (91.3%)
B 13 (30.2%) 30 (69.8%)
C 4 (44.4%) 5 (55.6%)
D 24 (82.8%) 5 (17.2%)
TASC II category
combined
<.01b
A and B 15 (22.7%) 51 (77.3%)
C and D 28 (73.7%) 10 (26.3%)
Preop mean ABI 0.47 0.59 .078
Postop mean ABI 0.91 0.91 .94
Mean ABI
improvement
(SD)
0.44 (0.05)
(n ¼ 30)
0.32 (0.04)
(n ¼ 49)
.068
ABI, Ankle brachial index; CAD, coronary artery disease; CVA, cerebro-
vascular accident; COPD, chronic obstructive pulmonary disease; SD,
standard deviation; TASC, TransAtlantic Inter-Society Consensus.
aTwo-tailed t-test with pooled variance.
bTwo-tailed Fisher exact test.
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TASC C and D lesions received bypass (P < .01). ABI
values were falsely elevated or missing in 13 patients in the
bypass group and 12 patients in the stent group. Although
the stent group had higher preoperative mean ABI than
the bypass group (0.59 vs 0.47; P¼ .078), the postoperative
mean ABI was the same in both groups (0.91; P ¼ .94).
There was signiﬁcant and similar improvement in mean
ABI for both stent and bypass groups postoperatively
(0.32 vs 0.44; P ¼ .068) Table I.
The cumulative proportion of primary patency at 24
months, using the Kaplan-Meier survival estimates, was
67% in the stent group (95% CI, 0.52-0.78) vs 49% in
the bypass group (95% CI, 0.32-0.64; P ¼ .05) (Fig 1).
There were 23 reintervention procedures in 16 patients
(37%) in the bypass group (20 with PTA, two with interpo-
sition vein graft, and one with vein patch angioplasty)
compared with 19 intervention procedures in 14 patients
(22.9%) in the stent group (15 with PTA and four with
PTA/S). The rate of reintervention within the 2-year
period was higher in the bypass group compared with the
stent group (53.5% vs 31%; P ¼ .02). The cumulative
proportion of patients with primary-assisted patency was
similar for patients receiving stent 73% (95% CI, 0.56-
0.85) vs bypass 81% (95% CI, 0.67-0.90; P ¼ .36) (Fig 2).Survival analysis showed no signiﬁcant difference in the
maintenance of patency across TASC II groups comparing
stent vs bypass. However, when TASC II groups A and B
were combined and compared with the combined groups
of TASC II C and D, patency was greater among the ﬁrst
group (log-rank P ¼ .01) (Fig 3).
Cox proportional hazard models demonstrated a trend
toward reduced risk of primary patency failure among
patients receiving stents compared with those undergoing
bypass procedures (HR, 0.53; 95% CI, 0.28-1.01; P ¼
.06). However, this trend was lost after adjusting for
patients’ characteristics and lesions’ TASC II types (HR,
0.73; 95% CI, 0.28-1.90; P ¼ .52) (Table II). TASC C
and D lesions combined demonstrated a 2.8-fold increase
in hazard of patency failure compared with TASC A and
B lesions combined (HR, 2.81; 95% CI, 1.13-6.69; P ¼
.02) (Table II). Females had an almost twofold increase
in hazard of patency failure (HR, 1.99; 95% CI, 1.10-
3.90; P ¼ .04) (Table II). There was no signiﬁcant differ-
ence in the mortality rate (mortality incidence rate ratio,
1.54; 95% CI, 0.08-90.8; P ¼ .77). The limb salvage rate
was similar in both groups (90.7% in the bypass group vs
93.5% in the stent group; P ¼ .55).DISCUSSION
The 2-year primary-assisted patency rate of femoral-
popliteal above the knee bypass with autogenous graft is
81%.1 However, these ﬁgures represent 15-year-old data
prior to the popularity of the endovascular approach. We
believe that the majority of patients receiving bypass in
today’s practice have much more advanced disease. In
our group 74% of patients with TASC II C and D lesions
received a bypass. It is not surprising that these bypasses
would have lower patency than the historically reported
data.
Fig 3. Primary patency for all patients (stent vs bypass), adjusted
for TransAtlantic Inter-Society Consensus (TASC) II lesion type.
Fig 2. Primary-assisted patency in the stent group compared with
the bypass group.
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design made of nitinol (a mixture of nickel and titanium).
They are designed to accommodate the severe stresses
encountered in the SFA, including angulations, rotation,
and longitudinal compression.11 Improved durability of
stenting in the femoral artery has been reported with the
use of nitinol stents.12-16 In three prospective randomized
trials, Randomized Study Comparing the Edwards Self-
Expanding Lifestent vs Angioplasty Alone in Lesions
Involving the Superﬁcial Femoral Artery and/or Proximal
Popliteal Artery (RESILIENT),17 The Femoral Artery
Stenting Trial (FAST),18 and the Vienna study,19 adding
a self-expanding nitinol stent signiﬁcantly improved the
6- to 12-month patency rate of PTA alone in TASCA lesions(Table III). The ﬁrst generation of drug eluting stents using
polymer and Limus drug coating did not show a signiﬁcant
improvement in primary patency compared with bare metal
stent.16More recently, in a randomized clinical trial, nonpol-
ymer Paclitaxel coatedZilver PTX stents (CookMedical Inc,
Bloomington, Ind) are showing promising results with
improved 2-year primary patency compared with bare metal
stent (81% vs 63%, respectively; P < .01).20 Surowiec et al
performed a retrospective analysis comparing PTA 6 S
with bypass and reported a similar 2-year primary patency
of the endovascular group compared with our study6
(Table IV). The length of the lesion inversely related to the
patency for the stent. TASC A lesions had similar patency
to vein grafts, whereas TASC B lesions had similar patency
to PTFE grafts.6 The comparison group in this study was
from patients who underwent a bypass 8-13 years prior to
the popularity of the endovascular-ﬁrst approach. Dearing
et al reported 80% 1-year primary patency for primary
stenting of TASC II A and B lesions compared with 50% in
TASC II C and D lesions.7 The 2-year primary-assisted
patency in this study was comparable to our results (75%
vs 81%). The prior two studies both recommended an
endovascular option for TASC II A and B lesions and
bypass for TASC II C and D lesions. This is consistent
with the most recent TASC II recommendations.5
However, the treatment choice remains largely biased by
the treating physician’s comfort and experience and not
necessarily based on the durability of treatment method.
McQuade et al conducted a prospective randomized study
comparing femoral-popliteal bypass with synthetic grafts to
endovascular stenting with expanded PTFE/nitinol self-
expanding stent graft (Viabahn; W. L. Gore, Flagstaff,
Ariz).21 This study showed no signiﬁcant difference in
primary and secondary patency at 1-, 2-, 3-, and 4-year
follow-up between the two groups. The 1-year primary
patency of the stent graft was similar to the prior two
studies and to our own nitinol stent group. However,
the 2-year secondary patency was slightly lower than our
primary-assisted patency for the stent and bypass groups
(Table IV). Most of our patients in the bypass group
received an autogenous graft (88%), and all the patients
in the endovascular group received a self-expanding non-
covered nitinol stent. Table IV summarizes the primary
and primary-assisted patency of PTA/S among the last
three studies in comparison with our study. Our limb
salvage rate was similar in both groups.
TheBasil trial compared angioplastyﬁrstwithbypassﬁrst
for patients presenting with severe limb ischemia because of
infrainguinal disease. The long-term follow-up showed no
signiﬁcant difference in amputation free survival and overall
survival up to 2-year follow-up. However, patients who
survived beyond the 2 years did better in the surgical group.
The immediate failure rate of angioplasty was as high as 25%,
and the re-intervention rate was signiﬁcantly higher in this
group compared with the bypass group.22 There are several
factors that might have contributed to the different results in
our study. First, theBasil trial has included patientswith both
above and below knee disease. The durability of above knee
Table II. Analysis of factors associated with loss of patency
Characteristics
Unadjusted Adjusteda
HR (95% CI) P value HR (95% CI) P value
Treatment
Bypass Reference Reference
Stent 0.53 (0.28-1.01) .06 0.73 (0.28-1.90) .52
TASC lesion combined
TASC A and B Reference
TASC C and D 2.42 (1.26-4.65) <.01 2.81 (1.13-6.69) .02
TASC lesion
A Reference
B 0.41 (0.16-1.0) .06 0.34 (0.13-0.87) .02
C 0.84 (0.19-3.68) .82 0.82 (0.12-5.55) .83
D 1.67 (0.78-3.57) .19 1.79 (0.59-5.44) .30
Female 1.43 (0.75-2.73) .28 1.99 (1.10-3.90) .04
Smoking History 1.14 (0.57-2.31) .71 1.20 (0.64-2.25) .56
Diabetes 1.56 (0.78-3.09) .20 2.13 (0.81-5.66) .13
Hyperlipidemia 0.79 (0.36-1.75) .57 0.91 (0.33-0.45) .85
Hypertension 0.50 (0.25-1.00) .05 0.33 (0.16-0.65) <.01
CVA 2.12 (0.84-5.34) .11 2.31 (0.88-6.06) .08
COPD 0.73 (0.31-1.70) .47 0.94 (0.37-2.41) .89
CI, Conﬁdence interval; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; TASC, TransAtlantic Inter-Society
Consensus.
aAdjusted for lesion length and patient characteristics.
Table III. Summary of the results of three prospective randomized trials comparing the patency of PTA alone vs PTA
with nitinol stent
Trials Patients Stent type Mean length PTA patency PTA/S patency
RESILIENT 206 Life Stent 6.5 cm 45% (12-month) 87% (12-month)
FAST 244 Luminex 4.5 cm 61.7% (6-month) 74.5% (6-month)
Vienna 104 Various nitinol stents 5.9 cm 37% (12-month) 63% (12-month)
FAST, Femoral Artery Stenting Trial; PTA, percutaneous transluminal angioplasty; RESILIENT, Randomized Study Comparing the Edwards Self-Expanding
Lifestent vs Angioplasty Alone in Lesions Involving the Superﬁcial Femoral Artery and/or Proximal Popliteal Artery; S, stenting.
Table IV. Comparison of the results of our study to the most recent published studies evaluating the primary and
primary-assisted patency for PTA/S of the SFA
Study Year No. Follow-up Primary patency Assisted patency TASC
Surowiec6 2005 380 24-month 66% - A > B > C > D
A ¼ vein, B ¼ PTFE
McQuade20 2010 100 24-month 63% 74% No difference
Dearing7 2011 239 24-month 55% 75% A and B > C and D
Malas 2012 104 24-month 67% 81% A and B > C and D
PTA, Percutaneous transluminal angioplasty; PTFE, polytetraﬂuoroethylene; S, stenting; SFA, superﬁcial femoral artery; TASC, TransAtlantic Inter-Society
Consensus.
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teal and tibial interventions. Second, all of our patients
received a stent in addition to angioplasty, which is different
than the Basil trial where patients in the endovascular group
underwent angioplasty only.
Our study has several limitations. The sample size is
small (104 patients), which resulted in reducing the ability
of the model to show a statistically signiﬁcant association
of several of the covariates with the outcome variable.
Another important limitation in this study is the strongcorrelation between lesion characteristics and the procedure
chosen.Our study is confounded by indication and selection
bias because most long lesions were selected for bypass,
whereas most of the short lesions were selected for stenting.
CONCLUSIONS
Open bypass remains the gold standard for revascular-
ization of the lower extremity. This treatment method has
been extensively evaluated in several prospective well-
designed studies, which have shown it to be effective in
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 1 Malas et al 135long-term limb salvage and improving patients’ quality of
life.Nevertheless, over the last decade there has been a signif-
icant shift in the treatment paradigm with an endovascular
ﬁrst approach on all patients evolving in many centers.
Therefore, patients undergoing a bypass graft today have
much more advanced disease. This is the ﬁrst study that
demonstrates a higher rate of reintervention for femoral-
popliteal bypass compared with angioplasty and stenting.
It also clearly demonstrates that the two patient populations
are not equivalent, withmuchmore extensive disease treated
in the bypass cohort. This study illustrates the strong neces-
sity for a well-designed prospective randomized trial to
compare the two treatment modalities, which we are
currently conducting in our institution. This will help elim-
inate the selection bias in retrospective study and provide
level-one evidence on the effectiveness of both procedures.
Special acknowledgment to Taylor Reed and Yanjun J.
Xie for their effort with data extraction.
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